☒ |
ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
|
☐ |
TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
|
Delaware
|
77-0390628
|
|
(State or other jurisdiction of incorporation or organization)
|
(I.R.S. Employer Identification No.)
|
308 Dorla Court, Suite 206
Zephyr Cove, Nevada |
89448
|
|
(Address of principal executive offices)
|
(Zip Code)
|
Title of each class
|
Trading Symbol(s)
|
Name of each exchange on which registered
|
||
Common Stock, par value $0.0001 per share
|
VHC
|
NYSE
|
Large accelerated filer ☐
|
Accelerated filer ☐
|
Non-accelerated filer ☒
|
Emerging growth company ☐
|
Smaller reporting company ☒
|
|
Page
|
|
PART I
|
||
Item 1.
|
3
|
|
Item 1A.
|
10
|
|
Item 1B.
|
24
|
|
Item 2.
|
24
|
|
Item 3.
|
24
|
|
Item 4.
|
24
|
|
PART II
|
||
Item 5.
|
25
|
|
Item 6.
|
25
|
|
Item 7.
|
25
|
|
Item 7A.
|
34
|
|
Item 8.
|
35
|
|
Item 9.
|
56
|
|
Item 9A.
|
56
|
|
Item 9B.
|
56
|
|
PART III
|
||
Item 10.
|
57
|
|
Item 11.
|
57
|
|
Item 12.
|
57
|
|
Item 13.
|
57
|
|
Item 14.
|
57
|
|
PART IV
|
||
Item 15.
|
58
|
Item 1. |
Business
|
• |
Actively recruit partners in various vertical markets, including healthcare, finance, legal, government to help us rapidly expand our enterprise customer base.
|
• |
Continue to grow our technology licensing program to commercialize our intellectual property, including our GABRIEL Connection Technology™.
|
• |
Promote our Gabriel Secure Communication Platform™ as a solution for delivering ZTNA.
|
• |
Grow our GABRIEL Gateway product offering to secure enterprise applications, services, and infrastructure.
|
• |
Grow registration of GABRIEL Secure Domains as the network segmentation component of our ZTNA solution. Establish VirnetX as the exclusive, universal registry of secure domain names and enable our customers to act as registrars for their users and broker secure communication between devices.
|
• |
Promote Gabriel Collaboration Suite™ products in the general market for sale to end-user enterprises, directly and with partners, with targeted promotions and other marketing programs. Expand GABRIEL Collaboration Suite™ to include video conferencing to assist remote workers and offer an industry leading secure meeting solution.
|
• |
Unique, certificate-based device identities, tied to a user, that are used to authenticate and authorize device access (e.g., GABRIEL Connection Technology™), based on a set of policies.
|
• |
Flexible, software-based network segmentation that enterprises can deploy on-demand, without requiring additional hardware infrastructure.
|
• |
Unique patented technology. We are focused on developing innovative technology for securing real-time communications over the Internet and establishing the exclusive secure domain name registry in the United States and other key markets around the world. Our unique solutions combine industry standard encryption methods and communication protocols with our patented techniques for automated DNS lookup mechanisms. Our technology and patented approach enable users to create a secure communication link by generating secure domain names. We currently own approximately 194 total patents and pending applications, including 70 U.S. patents/patent applications and 124 foreign patents/validations/pending applications. Our portfolio includes patents and pending patent applications in the United States and other key markets that support our secure domain name registry service for the Internet.
|
• |
Scalable licensing business model. We are actively engaged in pursuing additional licensing agreements with OEMs, service providers and system integrators within the IP-telephony, mobility, mobile-to-mobile communications, fixed-mobile convergence, and unified communications end-markets.
|
• |
Highly experienced research and development team. Our research and development team is comprised of nationally recognized network security and encryption technology scientists and experts that have worked together as a team for over ten years. During their careers, this team has developed several cutting-edge technologies for U.S. national defense, intelligence, and civilian agencies, many of which remain critical to our national security today. Prior to joining VirnetX, our team worked for Leidos, during which time they invented the technology that is the foundation of our technology, and software. Based on the collective knowledge and experience of our development team, we believe that we have one of the most experienced and sophisticated groups of security experts researching vulnerability and threats to real-time communication over the Internet and developing solutions to mitigate these problems.
|
• |
VirnetX technology licensing. Customers who want to develop their own implementation of the VirnetX code module for supporting secure domain names, or who want to use their own techniques that are covered by our patent portfolio for establishing secure communication links, could purchase a technology license. We anticipate that these licenses would typically include an initial license fee, as well as an ongoing royalty. We expect that these licenses will include a one-time delivery of GABRIEL software development kit including object libraries, sample code, testing and quality assurance tools and the supporting documentation necessary for a customer to implement of the techniques we have developed.
|
• |
GABRIEL Connection Technology™ Software Development Kit or SDK. OEM customers who want to adopt the GABRIEL Connection Technology™ as their solution for establishing secure connections using secure domain names within their products could purchase an SDK license. The software development kit consists of object libraries, sample code, testing and quality assurance tools and the supporting documentation necessary for a customer to implement our technology. These tools are comprised of software for a secure domain name connection test server, a relay test server, and a registration test server. We expect that customers would pay an up-front license fee to purchase an SDK license and a royalty fee for every product shipped with the embedded VirnetX code module.
|
• |
Secure domain name registrar service. Customers, including service providers, telecommunication companies, ISPs, system integrators and OEMs could purchase a license to our secure domain name registrar service. We would provide the software suite and technology support to enable such customers to provision devices with secure domain names and facilitate secure connections between registered devices. This suite includes the following server software modules:
|
• |
Registrar server software. We anticipate that our registrar server software would enable customers to operate as a secure domain name registrar that provisions devices with secure domain names. The registrar server software is designed to provide an interface for our customers to register new virtual private domains and sub-domain names. This server module must be enrolled with the VirnetX secure domain name master registry to obtain its credentials before functioning as an authorized registrar.
|
• |
Connection server software. We anticipate that our connection server software would allow customers to provide connection services to enrolled devices. The connection services include registration of presence information for authenticated users and devices, presence information query request services, enforcement of policies and support for communication with peers behind firewalls.
|
• |
Relay server software. We anticipate that our relay server software would allow customers to dynamically maintain connections and relay data to private IP addresses for network devices that reside behind firewalls.
|
• |
Secure domain name master registry and connection service. As part of enabling the secure domain name registrar service, we expect that we will maintain and manage the secure domain name master registry. This service is expected to enroll all secure domain name registrar customers and generate the credentials required to function as an authorized registrar. It also is expected to provide connection services and universal name resolution, presence information and secure connections between authorized devices with secure domain names. Secure domain name registrar service customers will enter into a technology licensing and revenue sharing agreement with VirnetX whereby we will typically receive an up-front licensing fee for the secure domain name registrar technology, as well as ongoing annual royalties for each secure domain name issued by the customer.
|
• |
Technical support services. We intend to provide high-quality technical support services to licensees and customers for the rapid customization and deployment of GABRIEL Connection Technology™ in an individual customer’s products and services.
|
• |
Patent Assignment. Leidos, unconditionally and irrevocably conveyed, transferred, assigned, and quitclaimed all its right, title, and interest in and to the patents and patent applications, as specifically set forth on Exhibit A to the assignment document recorded with the U.S. Patent Office, including, without limitation, the right to sue for past infringement.
|
• |
License to Leidos, Outside the Field of Use. Effective March 12, 2008, we granted to Leidos, a non-exclusive, royalty free, fully paid, perpetual, worldwide, irrevocable, sub licensable and transferable right and license permitting Leidos, and its assignees to make, have made, import, use, offer for sale, and sell products and services covered by, and to make improvements to, the patents and patent applications we acquired from Leidos, solely outside our field of use.
|
• |
Compensation Obligations. As consideration for the assignment of the patents and for the rights we obtained from Leidos, as amended, we are required to make payments to Leidos, based on cash or certain other values generated from those patents. The amount of such payments depends upon the type of value generated, and certain categories are subject to maximums and other limitations. In 2010, we met our maximum royalty payment requirement; however, Leidos is also entitled under certain circumstances to receive a portion of the proceeds paid to us for certain acquisitions of VirnetX and the settlement of certain patent infringement claims of ours.
|
• |
Third parties may challenge the validity of our patents;
|
• |
The pendency of our various litigations may cause potential licensees not to do business with us;
|
• |
Our patents may expire before we can make our business strategy successful;
|
• |
We face, and we expect to continue to face, intense competition from new and established competitors who may have superior products and services or better marketing, financial or other capacities than we do; and
|
• |
It is possible that one or more of our potential customers or licensees develops or otherwise sources products or technologies similar to, competitive with or superior to ours.
|
• |
New legislation, regulations or rules related to obtaining patents or enforcing patents could significantly increase our operating costs and decrease our revenue. For instance, the United States Supreme Court has modified some tests used by the USPTO in granting patents during the past 20 years which may decrease the likelihood that we will be able to obtain patents and increase the likelihood of challenge of any patents we obtain or license. In addition, in 2012 the United States enacted sweeping changes to the United States patent system under the Leahy-Smith America Invents Act, including changes that transition the United States from a “first-to-invent” system to a “first to file” system and alter the processes for challenging issued patents;
|
• |
More patent applications are filed each year resulting in longer delays in getting patents issued by the USPTO;
|
• |
Federal courts are becoming more crowded, and as a result, patent enforcement litigation is taking longer; and
|
• |
As patent enforcement becomes more prevalent, it may become more difficult for us to voluntarily license our patents.
|
• |
The need to educate potential customers about our patent rights and our product and service capabilities;
|
• |
The impact of the COVID-19 pandemic on our potential customers and their business operations, including their budgetary constraints and resources devoted to adopting new products.
|
• |
Our customers’ willingness to invest potentially substantial resources and modify their network infrastructures to take advantage of our products;
|
• |
Our customers’ budgetary constraints;
|
• |
The timing of our customers’ budget cycles;
|
• |
Delays caused by customers’ internal review processes; and
|
• |
Long sales cycles that may increase the risk that our financial resources are exhausted before we are able to generate significant revenue.
|
• |
Generate revenues or profit from product sales;
|
• |
Drive adoption of our products;
|
• |
Attract and retain customers for our products;
|
• |
Provide appropriate levels of customer training and support for our products;
|
• |
Implement an effective marketing strategy to promote awareness of our products;
|
• |
Focus our research and development efforts in areas that generate returns on our efforts;
|
• |
Anticipate and adapt to changes in our market; or
|
• |
Protect our products from any system failures or other breaches.
|
• |
Power loss, transmission cable cuts and other telecommunications failures;
|
• |
Damage or interruption caused by fire, earthquake, and other natural disasters;
|
• |
Computer viruses or software defects; and
|
• |
Physical or electronic break-ins, sabotage, intentional acts of vandalism, terrorist attacks and other events beyond our control.
|
• |
Developments or lack thereof in any then-outstanding litigation;
|
• |
Quarterly variations in our operating results;
|
• |
Large purchases or sales of common stock or derivative transactions related to our stock;
|
• |
Actual or anticipated announcements of new products or services by us or competitors;
|
• |
General conditions in the markets in which we compete; and
|
• |
General social, political, economic, and financial conditions, including the significant volatility in the global financial markets, and impacts from the COVID-19 pandemic.
|
• |
Price and volume fluctuations in the overall stock market from time to time, including fluctuations due to general economic uncertainty or negative market sentiment, in particular related to the COVID-19 pandemic;
|
• |
Volatility in the market prices and trading volumes of companies in our industry or companies that investors consider comparable;
|
• |
Changes in operating performance and stock market valuations of other companies generally, or those in our industry;
|
• |
Sales of shares of our common stock by us or our stockholders;
|
• |
Failure of securities analysts to maintain coverage of us, changes in financial estimates by securities analysts who follow us, or our failure to meet these estimates or the expectations of investors;
|
• |
The financial projections we may provide to the public, any changes in those projections or our failure to meet those projections;
|
• |
Announcements by us or our competitors of new products or services;
|
• |
The public’s reaction to our press releases, other public announcements, and filings with the SEC;
|
• |
Rumors and market speculation involving us or other companies in our industry;
|
• |
Actual or anticipated changes in our results of operations;
|
• |
Actual or anticipated developments in our business, our competitors’ businesses, or the competitive landscape generally;
|
• |
Litigation involving us, our industry or both, or investigations by regulators into our operations or those of our competitors;
|
• |
Announced or completed acquisitions of businesses or technologies by us or our competitors;
|
• |
New laws or regulations or new interpretations of existing laws or regulations applicable to our business;
|
• |
Changes in accounting standards, policies, guidelines, interpretations, or principles;
|
• |
Any significant change in our management; and
|
• |
General economic conditions and slow or negative growth of our markets, including any economic downturn from the COVID-19 pandemic;
|
• |
The outcome of actions to enforce our intellectual property rights currently in progress or that we may undertake in the future, and the timing thereof;
|
• |
The impact of the COVID-19 pandemic on our sales cycle and results;
|
• |
The amount and timing of receipt of license fees from potential infringers, licensees, or customers;
|
• |
The rate of adoption of our patented technologies;
|
• |
The number of new license arrangements we may execute, or that may expire, within a particular period and the scope of those licenses, including the number of our patents which are licensed, the extent of prior infringement of our patent rights, royalty rates, timing of payment obligations, expiration date etc.;
|
• |
The success of a licensee in selling products that use our patented technologies; and
|
• |
The amount and timing of expenses related to our patent filings and enforcement proceedings, including litigation, related to our intellectual property rights.
|
• |
A staggered Board of Directors: This means that only one or two directors (since we have a five-person Board of Directors) will be up for election at any given annual meeting. This has the effect of delaying the ability of stockholders to affect a change in control of us because it would take two annual meetings to effectively replace a majority of the Board of Directors.
|
• |
Blank check preferred stock: Our Board of Directors has the authority to establish the rights, preferences, and privileges of our 10,000,000 authorized, but unissued, shares of preferred stock. Therefore, this stock may be issued at the discretion of our Board of Directors with preferences over your shares of our common stock in a manner that is materially dilutive to you. In addition, blank check preferred stock can be used to create a “poison pill” which is designed to deter a hostile bidder from buying a controlling interest in our stock without the approval of our Board of Directors. We have not adopted such a “poison pill;” but our Board of Directors has the ability to do so in the future, very rapidly and without stockholder approval.
|
• |
Advance notice requirements for director nominations and for new business to be brought up at stockholder meetings: Stockholders wishing to submit director nominations or raise matters to a vote of the stockholders must provide notice to us within very specific date windows and in very specific form in order to have the matter voted on at a stockholder meeting. This has the effect of giving our Board of Directors and management more time to react to stockholder proposals generally and could also have the effect of disregarding a stockholder proposal or deferring it to a subsequent meeting to the extent such proposal is not raised properly.
|
• |
No stockholder actions by written consent: No stockholder or group of stockholders may take actions rapidly and without prior notice to our Board of Directors and management or to the minority stockholders. Along with the advance notice requirements described above, this provision also gives our Board of Directors and management more time to react to proposed stockholder actions.
|
• |
Super majority requirement for stockholder amendments to the bylaws: Stockholder proposals to alter or amend our bylaws or to adopt new bylaws can only be approved by the affirmative vote of at least 66 2/3% of the outstanding shares of our common stock.
|
• |
No ability of stockholders to call a special meeting of the stockholders: Only the Board of Directors or management can call special meetings of the stockholders. This could mean that stockholders, even those who represent a significant percentage of our shares of common stock, may need to wait for the annual meeting before nominating directors or raising other business proposals to be voted on by the stockholders.
|
Item 1B. |
Unresolved Staff Comments.
|
Item 2. |
Properties
|
Item 3. |
Legal Proceedings (See “Litigation” in Item 7 - Management’s Discussion and Analysis of Financial Condition and Results of Operations)
|
Item 4. |
Mine Safety Disclosure
|
Item 5. |
Market for the Registrant’s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities
|
Item 6. |
Not applicable
|
Item 7. |
Management’s Discussion and Analysis of Financial Condition and Results of Operations
|
2020
|
2019
|
|||||||
Revenue
|
$
|
302,636
|
$
|
85
|
2020
|
2019
|
|||||||
Research and Development
|
$
|
8,830
|
$
|
3,845
|
2020
|
2019
|
|||||||
Selling, General and Administrative
|
$
|
45,812
|
$
|
15,905
|
2020
|
2019
|
|||||||
Interest and Other Income
|
$
|
108,288
|
$
|
92
|
|
Year Ended
December 31, 2020
|
Year Ended
December 31, 2019
|
|||||||
United States federal statutory rate
|
21.00
|
%
|
21.00
|
%
|
|||||
State taxes, net of federal benefit
|
0.17
|
%
|
1.99
|
%
|
|||||
Valuation allowance
|
(12.22
|
) %
|
(21.96
|
) %
|
|||||
Stock based compensation
|
(0.01
|
) %
|
—
|
||||||
R&D Credit
|
(0.21
|
) %
|
1.34
|
%
|
|||||
Other
|
0.06
|
%
|
(0.38
|
) %
|
|||||
Effective income tax rate
|
8.79
|
%
|
1.99
|
%
|
Item 7A. |
Quantitative and Qualitative Disclosures about Market Risk
|
|
Page
|
36
|
|
38
|
|
39
|
|
39
|
|
40
|
|
41
|
|
42
|
|
As of
December 31, 2020
|
As of
December 31, 2019
|
||||||
ASSETS
|
||||||||
Current assets:
|
||||||||
Cash and cash equivalents
|
$
|
192,908
|
$
|
3,135
|
||||
Investments available for sale
|
28,348
|
2,394
|
||||||
Accounts receivables
|
8
|
5
|
||||||
Prepaid income tax
|
2,905
|
—
|
||||||
Prepaid expenses and other current assets
|
263
|
237
|
||||||
Total current assets
|
224,432
|
5,771
|
||||||
Prepaid expenses and other assets
|
1,301
|
1,711
|
||||||
Property and equipment, net
|
11
|
16
|
||||||
Long term, deferred tax asset
|
9,049
|
—
|
||||||
Total assets
|
$
|
234,793
|
$
|
7,498
|
||||
LIABILITIES AND STOCKHOLDERS’ EQUITY
|
||||||||
Current liabilities:
|
||||||||
Accounts payable and accrued liabilities
|
$
|
654
|
$
|
1,346
|
||||
Accrued payroll and related expenses
|
220
|
287
|
||||||
Accrued licensing costs
|
9,438
|
—
|
||||||
Other liabilities, current
|
44
|
193
|
||||||
Total current liabilities
|
10,356
|
1,826
|
||||||
Other liabilities
|
—
|
44
|
||||||
Total liabilities
|
10,356
|
1,870
|
||||||
Commitments and contingencies (Note 4)
|
|
|
||||||
Stockholders’ equity:
|
||||||||
Preferred stock, par value $0.0001 per share Authorized: 10,000,000 shares at December 31, 2020 and December 31, 2019, Issued and outstanding: 0 shares at December 31, 2020 and December 31, 2019
|
—
|
—
|
||||||
Common stock, par value $0.0001 per share
|
||||||||
Authorized: 100,000,000 shares at December 31, 2020 and December 31, 2019, Issued and outstanding: 71,058,570 shares and 69,586,764 shares, at December 31, 2020 and December 31, 2019, respectively
|
7
|
7
|
||||||
Additional paid-in capital
|
232,457
|
223,237
|
||||||
Accumulated deficit
|
(8,014
|
)
|
(217,602
|
)
|
||||
Accumulated other comprehensive loss
|
(13
|
)
|
(14
|
)
|
||||
Total stockholders’ equity
|
224,437
|
5,628
|
||||||
Total liabilities and stockholders’ equity
|
$
|
234,793
|
$
|
7,498
|
|
Year Ended
December 31, 2020
|
Year Ended
December 31, 2019
|
||||||
Revenue
|
$
|
302,636
|
$
|
85
|
||||
Operating expense:
|
||||||||
Licensing costs
|
90,101
|
—
|
||||||
Research and development
|
8,830
|
3,845
|
||||||
Selling, general and administrative expenses
|
45,812
|
15,905
|
||||||
Total operating expense
|
144,743
|
19,750
|
||||||
Income (loss) from operations
|
157,893
|
(19,665
|
)
|
|||||
Gain on settlement
|
41,271
|
—
|
||||||
Interest and other income, net
|
108,288
|
92
|
||||||
Income (loss) before taxes
|
307,452
|
(19,573
|
)
|
|||||
Income tax (expense) benefit
|
(27,023
|
)
|
393
|
|||||
Net income (loss)
|
$
|
280,429
|
$
|
(19,180
|
)
|
|||
Basic earnings (loss) per share
|
$
|
3.96
|
$
|
(0.28
|
)
|
|||
Diluted earnings (loss) per share
|
$
|
3.92
|
$
|
(0.28
|
)
|
|||
Weighted average shares outstanding basic
|
70,850,311
|
68,564,321
|
||||||
Weighted average shares outstanding diluted
|
71,615,843
|
68,564,321
|
|
Year Ended
December 31, 2020 |
Year Ended
December 31, 2019 |
||||||
Net income (loss)
|
$
|
280,429
|
$
|
(19,180
|
)
|
|||
Other comprehensive (loss), net of tax:
|
||||||||
Change in unrealized gain (loss) on investments
|
—
|
3
|
||||||
Change in foreign currency translation
|
1
|
(3
|
)
|
|||||
Total other comprehensive gain (loss), net of tax
|
1
|
—
|
||||||
Comprehensive income (loss)
|
$
|
280,430
|
$
|
(19,180
|
)
|
|
Common Stock
|
Additional
|
Accumulated
Other |
Total
Stockholders’ |
||||||||||||||||||||
Shares
|
Amount
|
Paid-in
Capital |
Accumulated
Deficit
|
Comprehensive
Loss
|
Equity
|
|||||||||||||||||||
Balance at December 31, 2018
|
66,879,847
|
$
|
7
|
$
|
208,317
|
$
|
(198,422
|
)
|
$
|
(14
|
)
|
$
|
9,888
|
|||||||||||
Stock issued for cash at $4.00 -$6.49 per share, net
|
1,860,483
|
10,539
|
10,539
|
|||||||||||||||||||||
Stock issued for options and RSUs, net
|
846,434
|
670
|
670
|
|||||||||||||||||||||
Stock-based compensation
|
3,711
|
3,711
|
||||||||||||||||||||||
Comprehensive loss:
|
||||||||||||||||||||||||
Net loss
|
(19,180
|
)
|
(19,180
|
)
|
||||||||||||||||||||
Change in foreign currency translation, net of tax
|
(3
|
)
|
(3
|
)
|
||||||||||||||||||||
Change in unrealized gains, net of tax
|
3
|
3
|
||||||||||||||||||||||
Comprehensive loss
|
(19,180
|
)
|
||||||||||||||||||||||
Balance at December 31, 2019
|
69,586,764
|
$
|
7
|
$
|
223,237
|
$
|
(217,602
|
)
|
$
|
(14
|
)
|
$
|
5,628
|
|||||||||||
Stock issued for cash at $4.00 -$4.96 per share, net
|
1,049,382
|
4,488
|
4,488
|
|||||||||||||||||||||
Stock issued for options and RSUs, net
|
422,424
|
690
|
690
|
|||||||||||||||||||||
Stock-based compensation
|
3,938
|
3,938
|
||||||||||||||||||||||
Warrants issued for services
|
104
|
104
|
||||||||||||||||||||||
Dividends declared and paid, $1.00 per share
|
(70,841
|
)
|
(70,841
|
)
|
||||||||||||||||||||
Comprehensive income:
|
||||||||||||||||||||||||
Net income
|
280,429
|
280,429
|
||||||||||||||||||||||
Change in foreign currency translation, net of tax
|
1
|
1
|
||||||||||||||||||||||
Comprehensive income
|
280,430
|
|||||||||||||||||||||||
Balance at December 31, 2020
|
71,058,570
|
$
|
7
|
$
|
232,457
|
$
|
(8,014
|
)
|
$
|
(13
|
)
|
$
|
224,437
|
|
Year Ended
December 31, 2020 |
Year Ended
December 31, 2019 |
||||||
Cash flows from operating activities:
|
||||||||
Net income (loss)
|
$
|
280,429
|
$
|
(19,180
|
)
|
|||
Adjustments to reconcile net income (loss) to net cash provided by (used in) operating activities:
|
||||||||
Depreciation
|
5
|
7
|
||||||
Stock-based compensation
|
3,938
|
3,711
|
||||||
Amortization of warrant issuance costs
|
69
|
—
|
||||||
Deferred income taxes
|
(9,049
|
)
|
—
|
|||||
Changes in assets and liabilities:
|
||||||||
Prepaid expenses and other assets
|
419
|
374
|
||||||
Accounts payable and accrued liabilities
|
(692
|
)
|
296
|
|||||
Other liabilities
|
(193
|
)
|
97
|
|||||
Accrued payroll and related expenses
|
(67
|
)
|
10
|
|||||
Accrued licensing costs
|
9,438
|
—
|
||||||
Accounts receivable
|
(3
|
)
|
1
|
|||||
Prepaid income taxes
|
(2,905
|
)
|
(396
|
)
|
||||
Net cash provided by (used in) operating activities
|
281,389
|
(15,080
|
)
|
|||||
Cash flows from investing activities:
|
||||||||
Purchase of property and equipment
|
—
|
(14
|
)
|
|||||
Purchase of investments
|
(33,065
|
)
|
(5,784
|
)
|
||||
Proceeds from sale or maturity of investments
|
7,112
|
5,192
|
||||||
Net cash used in investing activities
|
(25,953
|
)
|
(606
|
)
|
||||
Cash flows from financing activities:
|
||||||||
Proceeds from exercise of options
|
1,046
|
816
|
||||||
Proceeds from sale of common stock
|
4,488
|
10,539
|
||||||
Payment of dividends on common stock
|
(70,841
|
)
|
—
|
|||||
Payments on payroll taxes on cashless vesting of RSUs
|
(356
|
)
|
(145
|
)
|
||||
Net cash (used in) provided by financing activities
|
(65,663
|
)
|
11,210
|
|||||
Net increase (decrease) in cash and cash equivalents
|
189,773
|
(4,476
|
)
|
|||||
Cash and cash equivalents, beginning of period
|
3,135
|
7,611
|
||||||
Cash and cash equivalents, end of period
|
$
|
192,908
|
$
|
3,135
|
||||
Cash paid for income taxes
|
$
|
38,977
|
$
|
4
|
|
December 31
|
|||||||
2020
|
2019
|
|||||||
Office furniture
|
$
|
79
|
$
|
79
|
||||
Computer equipment
|
81
|
81
|
||||||
Total
|
160
|
160
|
||||||
Less accumulated depreciation
|
(149
|
)
|
(144
|
)
|
||||
Total property and equipment, net
|
$
|
11
|
$
|
16
|
Options Outstanding
|
Options Vested and Exercisable
|
|||||||||||||||||||||||
Range of
Exercise Prices |
Number
Outstanding
|
Weighted
Average
Remaining
Contractual
Life (Years)
|
Weighted
Average
Exercise
Price
|
Number
Exercisable
|
Weighted
Average
Remaining
Contractual
Life (Years)
|
Weighted
Average
Exercise
Price
|
||||||||||||||||||
$ 2.35 - 6.95
|
4,558,896
|
7.04
|
$
|
4.53
|
3,147,625
|
6.47
|
$
|
4.26
|
||||||||||||||||
$ 14.52 - 35.25
|
1,253,625
|
1.71
|
$
|
23.16
|
1,253,625
|
1.71
|
$
|
23.16
|
||||||||||||||||
5,812,521
|
5.89
|
$
|
8.62
|
4,401,250
|
5.11
|
$
|
9.64
|
|
Options
|
|||||||||||||||
Number of
Shares
|
Weighted
Average
Exercise
Price
|
Weighted
Average
Remaining
Contractual
Life (Years)
|
Aggregate
Intrinsic
Value
|
|||||||||||||
Outstanding at December 31, 2018
|
5,998,837
|
$
|
7.72
|
—
|
$
|
—
|
||||||||||
Options granted
|
345,000
|
6.06
|
—
|
—
|
||||||||||||
Options exercised
|
(663,816
|
)
|
1.23
|
—
|
—
|
|||||||||||
Options cancelled
|
(50,000
|
)
|
4.95
|
—
|
—
|
|||||||||||
Outstanding at December 31, 2019
|
5,630,021
|
$
|
8.49
|
6.11
|
$
|
516
|
||||||||||
Options granted
|
747,500
|
6.07
|
—
|
—
|
||||||||||||
Options exercised
|
(262,031
|
)
|
3.99
|
—
|
—
|
|||||||||||
Options cancelled
|
(302,969
|
)
|
5.30
|
—
|
—
|
|||||||||||
Outstanding at December 31, 2020
|
5,812,521
|
$
|
8.55
|
5.89
|
$
|
3,650
|
||||||||||
Options exercisable at December 31, 2020
|
4,401,250
|
$
|
9.64
|
5.11
|
$
|
2,927
|
|
RSUs
|
|||||||||||
Number of
RSUs
|
Weighted
Average
Grant Date
Fair Value
|
Aggregate
Intrinsic
Value
|
||||||||||
Outstanding at December 31, 2018
|
504,994
|
$
|
3.83
|
$
|
—
|
|||||||
RSUs granted
|
229,996
|
6.06
|
—
|
|||||||||
RSUs vested
|
(207,334
|
)
|
4.07
|
—
|
||||||||
RSUs cancelled
|
(29,167
|
)
|
4.65
|
|||||||||
Outstanding at December 31, 2019
|
498,489
|
$
|
4.71
|
$
|
86
|
|||||||
RSUs granted
|
218,329
|
6.89
|
—
|
|||||||||
RSUs vested
|
(212,495
|
)
|
4.63
|
—
|
||||||||
Outstanding at December 31, 2020
|
504,323
|
$
|
5.69
|
$
|
230
|
Stock-Based Compensation by Type of Award
|
Year Ended
December 31, 2020
|
Year Ended
December 31, 2019
|
||||||
Stock options
|
$
|
2,872
|
$
|
2,756
|
||||
RSUs
|
1,066
|
955
|
||||||
Total stock-based compensation expense
|
$
|
3,938
|
$
|
3,711
|
|
Year Ended
December 31, 2020
|
Year Ended
December 31, 2019
|
||||||
Expected stock price volatility
|
93.45
|
%
|
92.34
|
%
|
||||
Risk-free interest rate
|
0.63
|
%
|
2.09
|
%
|
||||
Expected life term
|
6.21 years
|
6.14 years
|
||||||
Expected dividends
|
0
|
%
|
0
|
%
|
|
2020
|
2019
|
||||||
Net income (loss)
|
$
|
280,429
|
$
|
(19,180
|
)
|
|||
Basic weighted average number of shares outstanding
|
70,850
|
68,564
|
||||||
Effect of dilutive securities
|
766
|
—
|
||||||
Diluted weighted average number of shares outstanding
|
71,616
|
68,564
|
||||||
Basic earnings (loss) per share
|
$
|
3.96
|
$
|
(0.28
|
)
|
|||
Diluted earnings (loss) per share
|
$
|
3.92
|
$
|
(0.28
|
)
|
Warrants Issued
|
Exercise
Price
|
Outstanding and
Exercisable
December 31, 2019
|
Issued
|
Exercised
|
Terminated /
Cancelled
|
Outstanding and Exercisable
December 31, 2020
|
Expiration Date
|
25,000
|
$7.00
|
25,000
|
—
|
—
|
(25,000)
|
—
|
April 30, 2020
|
25,000
|
$5.75
|
—
|
25,000
|
—
|
—
|
25,000
|
April 30, 2025
|
|
—
|
25,000
|
25,000
|
—
|
(25,000)
|
25,000
|
—
|
|
Year Ended
December 31, 2020 |
Year Ended
December 31, 2019 |
||||||
Current:
|
||||||||
Federal
|
$
|
35,122
|
$
|
—
|
||||
State
|
950
|
(393
|
)
|
|||||
36,072
|
(393
|
)
|
||||||
Deferred:
|
||||||||
Federal
|
(8,816
|
)
|
—
|
|||||
State
|
(233
|
)
|
—
|
|||||
(9,049
|
)
|
—
|
||||||
Total income tax provision (benefit)
|
$
|
27,023
|
$
|
(393
|
)
|
|
Year Ended
December 31, 2020 |
Year Ended
December 31, 2019 |
||||||
United States federal statutory rate
|
21.00
|
%
|
21.00
|
%
|
||||
State taxes, net of federal benefit
|
0.17
|
%
|
1.99
|
%
|
||||
Valuation allowance
|
(12.22
|
)%
|
(21.96
|
)%
|
||||
Stock based compensation
|
(0.01
|
)%
|
—
|
|||||
R&D Credit
|
(0.21
|
)%
|
1.34
|
%
|
||||
Other
|
0.06
|
%
|
(0.38
|
)%
|
||||
Effective income tax rate
|
8.79
|
%
|
1.99
|
%
|
|
As of
December 31, 2020 |
As of
December 31, 2019 |
||||||
Deferred tax assets:
|
||||||||
Reserves and accruals
|
$
|
48
|
$
|
62
|
||||
Research and development credits and other credits
|
13
|
1,730
|
||||||
Net operating loss carry forward
|
598
|
27,907
|
||||||
Stock based compensation
|
8,998
|
8,402
|
||||||
Other
|
3
|
11
|
||||||
Total deferred tax assets
|
$
|
9,660
|
$
|
38,112
|
||||
Valuation allowance
|
(611
|
)
|
(38,112
|
)
|
||||
Deferred tax assets after valuation allowance
|
9,049
|
—
|
||||||
Total deferred tax liability
|
—
|
—
|
||||||
Net deferred tax assets
|
$
|
9,049
|
$
|
—
|
|
Year Ended
December 31, 2020 |
Year Ended
December 31, 2019 |
||||||
Balance at the beginning of the year
|
$
|
—
|
$
|
316
|
||||
Additions based on tax positions related to the current year
|
—
|
—
|
||||||
Additions for tax positions of prior years
|
—
|
—
|
||||||
Settlements
|
—
|
—
|
||||||
Lapse of applicable statute of limitations
|
—
|
(316
|
)
|
|||||
Balance at the end of the year
|
$
|
—
|
$
|
—
|
|
December 31, 2020
|
|||||||||||||||||||||||
Adjusted
Cost |
Unrealized
Gains |
Unrealized
Losses |
Fair
Value |
Cash
and Cash Equivalents |
Investments
Available for Sale |
|||||||||||||||||||
Cash
|
$
|
121,785
|
$
|
—
|
$
|
—
|
$
|
121,785
|
$
|
121,785
|
$
|
—
|
||||||||||||
Level 1:
|
||||||||||||||||||||||||
Mutual funds
|
70,996
|
—
|
—
|
70,996
|
70,996
|
—
|
||||||||||||||||||
U.S. agency securities
|
13,767
|
2
|
—
|
13,769
|
127
|
13,642
|
||||||||||||||||||
U.S. treasury securities
|
14,707
|
—
|
(1
|
)
|
14,706
|
—
|
14,706
|
|||||||||||||||||
99,470
|
2
|
(1
|
)
|
99,471
|
71,123
|
28,348
|
||||||||||||||||||
Total
|
$
|
221,255
|
$
|
2
|
$
|
(1
|
)
|
$
|
221,256
|
$
|
192,908
|
$
|
28,348
|
|
December 31, 2019
|
|||||||||||||||||||||||
Adjusted
Cost |
Unrealized
Gains |
Unrealized
Losses |
Fair
Value |
Cash
and Cash Equivalents |
Investments
Available for Sale |
|||||||||||||||||||
Cash
|
$
|
2,076
|
$
|
—
|
$
|
—
|
$
|
2,076
|
$
|
2,076
|
$
|
—
|
||||||||||||
Level 1:
|
||||||||||||||||||||||||
Mutual funds
|
613
|
—
|
—
|
613
|
613
|
—
|
||||||||||||||||||
U.S. agency securities
|
2,837
|
3
|
—
|
2,840
|
446
|
2,394
|
||||||||||||||||||
3,450
|
3
|
—
|
3,453
|
1,059
|
2,394
|
|||||||||||||||||||
Total
|
$
|
5,526
|
$
|
3
|
$
|
—
|
$
|
5,529
|
$
|
3,135
|
$
|
2,394
|
Item 9. |
Changes in and Disagreements with Accountants on Accounting and Financial Disclosure
|
Item 9A. |
Controls and Procedures
|
Item 9B. |
Other Information
|
Item 10. |
Directors, Executive Officers and Corporate Governance
|
Item 11. |
Executive Compensation
|
Item 12. |
Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters
|
Plan Category
|
Number of
Securities to be
Issued Upon
Exercise of
Outstanding
Options and
RSUs
|
Weighted-Average
Exercise Price of
Outstanding
Options and RSUs
|
Number of
Securities
Remaining
Available for
Future Issuance
Under Equity
Compensation
Plans
|
|||||||||
Equity compensation plans approved by security holders
|
6,316,844
|
$
|
8.32
|
545,210
|
||||||||
Equity compensation plans not approved by security holders
|
—
|
—
|
||||||||||
Total
|
6,316,844
|
$
|
8.32
|
545,210
|
Item 13. |
Certain Relationships and Related Transactions, and Director Independence
|
Item 14. |
Principal Accountant Fees and Services
|
Item 15. |
Exhibits and Financial Statement Schedules
|
(a) |
The following documents are filed as part of this Annual Report on Form 10-K
|
(1) |
Financial Statements: See the Index to Consolidated Financial Statements under Item 8 of this Annual Report on Form 10-K.
|
(2) |
Financial Statement Schedule: Financial statement schedules are omitted because they are not applicable, or the required information is shown in the financial statements or notes thereto. All other schedules are omitted because of the absence of conditions under which they are required or because the required information is given in the financial statements or the notes thereto.
|
(3) |
Exhibits: The documents listed in the Exhibit Index of this Annual Report on Form 10-K are incorporated by reference or are filed with this Annual Report on Form 10-K, in each case as indicated therein (numbered in accordance with Item 601 of Regulation S-K).
|
Exhibit
Number
|
Incorporated by reference herein
|
||||||||
Description
|
Form
|
Exhibit No.
|
Filing Date
|
File No.
|
|||||
Certificate of Incorporation of the Company.
|
8-K
|
3.1
|
11/01/2007
|
000-26895
|
|||||
By Laws of the Company.
|
8-K
|
3.2
|
11/01/2007
|
000-26895
|
|||||
Form of Warrant Agency Agreement by and between the Company and Corporate Stock Transfer, Inc. as Warrant Agent.
|
S-1/A
|
4.1
|
01/16/2009
|
333-153645
|
|||||
Form of Series I Warrant.
|
8-K
|
4.1
|
09/03/2009
|
001-33852
|
|||||
Specimen Common Stock Certificate.
|
S-3
|
4.1
|
07/30/2018
|
333-226413
|
|||||
Form of Senior Indenture
|
S-3
|
4.2
|
07/30/2018
|
333-226413
|
|||||
Form of Subordinated Indenture
|
S-3
|
4.4
|
07/30/2018
|
333-226413
|
|||||
Description of Capital Stock
|
|||||||||
Form of Indemnification Agreement by and between the Company and each of Kendall Larsen, Robert D. Short III, Gary Feiner, Michael F. Angelo, Thomas M. O’Brien and Richard Nance.
|
10-K
|
10.1
|
03/18/2019
|
001-33852
|
|||||
2007 Stock Plan, as amended on April 13, 2012.
|
10-Q
|
10.2
|
05/10/2012
|
001-33852
|
|||||
Amended Form of Stock Option Agreement – 2007 Stock Plan.
|
10-Q
|
4.5
|
05/10/2011
|
001-33852
|
|||||
Form of Restricted Stock Unit Award Agreement – 2007 Stock Plan.
|
10-Q
|
10.3
|
05/10/2012
|
001-33852
|
|||||
2013 Equity Incentive Plan.
|
DEF 14A
|
Appendix A
|
04/12/2013
|
001-33852
|
|||||
Form of Stock Option Agreement – 2013 Equity Incentive Plan.
|
10-K
|
10.6
|
03/02/2015
|
001-33852
|
|||||
Form of Restricted Stock Unit Agreement – 2013 Equity Incentive Plan.
|
10-K
|
10.7
|
03/02/2015
|
001-33852
|
|||||
Voting Agreement among the Company and certain of its stockholders, dated as of December 12, 2007.
|
10-K
|
10.11
|
03/31/2008
|
001-33852
|
|||||
Securities Purchase Agreement, dated as of September 2, 2009, by and between the Company and the Purchasers (as defined therein).
|
8-K
|
10.1
|
09/03/2009
|
001-33852
|
Exhibit
Number
|
Incorporated by reference herein
|
||||||||
Description
|
Form
|
Exhibit No.
|
Filing Date
|
File No.
|
|||||
Form of Registration Rights Agreement by and between the Company and the Purchasers (as defined therein).
|
8-K
|
10.2
|
09/03/2009
|
001-33852
|
|||||
Form of Underwriting Agreement between VirnetX Holding Corporation and Gilford Securities Incorporated.
|
S-1/A
|
1.1
|
01/16/2009
|
333-153645
|
|||||
Patent License and Assignment Agreement by and between the Company and Leidos, Inc. (formerly Science Applications International Corporation) dated as of August 12, 2005.
|
8-K
|
10.4
|
07/12/2007
|
000-26895
|
|||||
Amendment No. 1 to Patent License and Assignment Agreement by and between the Company and Leidos, Inc. dated as of November 2, 2006.
|
8-K
|
10.6
|
07/12/2007
|
000-26895
|
|||||
Amendment No. 2 to Patent License and Assignment Agreement by and between VirnetX, Inc. and Leidos, Inc. dated as of March 12, 2008.
|
8-K
|
10.1
|
03/18/2008
|
001-33852
|
|||||
Security Agreement by and between the Company and Leidos, Inc. dated as of August 12, 2005.
|
8-K
|
10.5
|
07/12/2007
|
000-26895
|
|||||
Assignment Agreement between the Company and Leidos, Inc. dated as of December 21, 2006.
|
8-K
|
10.7
|
07/12/2007
|
000-26895
|
|||||
Professional Services Agreement by and between the Company and Leidos, Inc. dated as of August 12, 2005.
|
8-K
|
10.8
|
07/12/2007
|
000-26895
|
|||||
Engagement Letter dated June 8, 2009, by and between McKool Smith, a professional corporation, and VirnetX, Inc.
|
10-Q
|
10.1
|
08/10/2009
|
001-33852
|
|||||
Engagement Letter dated April 15, 2010, by and between McKool Smith, a professional corporation, and VirnetX, Inc.
|
10-Q
|
10.1
|
05/07/2010
|
001-33852
|
|||||
Settlement and License Agreement, by and between Microsoft Corporation and VirnetX, Inc., dated May 14, 2010.
|
10-Q/A
|
10.1
|
01/31/2011
|
001-33852
|
|||||
Amended Settlement and License Agreement, by and between Microsoft Corporation and VirnetX, Inc., dated December 17, 2014.
|
10-K
|
10.23
|
03/02/2015
|
001-33852
|
|||||
Employment Offer Letter from VirnetX, Inc. to Richard H. Nance.
|
10-Q
|
10.4
|
05/10/2012
|
001-33852
|
|||||
Amended and Restated Revenue Sharing Agreement by and between VirnetX Holding Corporation and Public Intelligence Technology Associates, dated October 18, 2017.
|
10-Q
|
10.1
|
11/09/2017
|
001-33852
|
Exhibit
Number
|
Incorporated by reference herein
|
||||||||||
Description
|
Form
|
Exhibit No.
|
Filing Date
|
File No.
|
|||||||
Amended and Restated Gabriel License Agreement by and between VirnetX Holding Corporation and Public Intelligence Technology Associates, dated October 18, 2017.
|
10-Q
|
10.2
|
11/09/2017
|
001-33852
|
|||||||
Sales Agreement, dated August 31, 2018, by and between VirnetX Holding Corporation and Cowen and Company, LLC.
|
8-K
|
10.1
|
08/31/2018
|
001-33852
|
|||||||
Subsidiaries of VirnetX Holding Corporation.
|
|||||||||||
Consent of Farber Hass Hurley LLP, Independent Registered Public Accounting Firm.
|
|||||||||||
Power of Attorney (contained on signature page hereto)
|
|||||||||||
Chief Executive Officer Certification pursuant to Rule 13a-14(a) of the Securities Exchange Act.
|
|||||||||||
Chief Financial Officer Certification pursuant to Rule 13a-14(a) of the Securities Exchange Act.
|
|||||||||||
Chief Executive Officer Certification pursuant to 18 U.S.C. Section 1350 as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002
|
|||||||||||
Chief Financial Officer Certification pursuant to 18 U.S.C. Section 1350 as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
|
|||||||||||
101.INS
|
XBRL Instance Document
|
||||||||||
101.SCH
|
XBRL Taxonomy Extension Schema Document
|
||||||||||
101.CAL
|
XBRL Taxonomy Extension Calculation Linkbase Document
|
||||||||||
101.DEF
|
XBRL Taxonomy Extension Definition Linkbase Document
|
||||||||||
101.LAB
|
XBRL Taxonomy Extension Label Linkbase Document
|
||||||||||
101.PRE
|
XBRL Taxonomy Extension Presentation Linkbase Document
|
||||||||||
* |
Indicates management contract or compensatory plan.
|
** |
Confidential treatment has been granted by the Securities and Exchange Commission as to certain portions of this Exhibit.
|
*** |
Portions of this Exhibit have been omitted pending a determination by the Securities and Exchange Commission as to whether these portions should be granted confidential treatment.
|
† |
The certifications attached as Exhibit 32.1 and 32.2 that accompany this Annual Report on Form 10-K are not deemed filed with the Securities and Exchange Commission and are not to be incorporated by reference into any filing of VirnetX Holding Corporation under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended, whether before or after the date of this Annual Report on Form 10-K, irrespective of any general incorporation language contained in such filing.
|
VirnetX Holding Corporation
|
|||
By:
|
/s/ Kendall Larsen
|
||
Name: Kendall Larsen
|
|||
Title: Chief Executive Officer and President
|
Name
|
Capacity
|
Date
|
||
/s/ Kendall Larsen
|
Director, Chief Executive Officer and President
|
March 16, 2021
|
||
Kendall Larsen
|
(Principal Executive Officer)
|
|||
/s/ Richard H. Nance
|
Chief Financial Officer
|
March 16, 2021
|
||
Richard H. Nance
|
(Principal Financial Officer and
Principal Accounting Officer)
|
|||
/s/ Robert D. Short III
|
Director
|
March 16, 2021
|
||
Robert D. Short III
|
||||
/s/ Gary Feiner
|
Director
|
March 16, 2021
|
||
Gary Feiner
|
||||
/s/ Michael F. Angelo
|
Director
|
March 16, 2021
|
||
Michael F. Angelo
|
||||
/s/ Thomas M. O’Brien
|
Director
|
March 16, 2021
|
||
Thomas M. O’Brien
|
|
• |
Undesignated Preferred Stock. The ability to authorize undesignated preferred stock makes it possible for our board of directors to issue one or more series of preferred
stock with voting or other rights or preferences that could impede the success of any attempt to change control of our company. These and other provisions may have the effect of deferring hostile takeovers or delaying changes in control or
management of our company.
|
|
• |
Stockholder Meetings. Our charter documents provide that a special meeting of stockholders may be called only by resolution adopted by the board of directors.
|
|
• |
Requirements for Advance Notification of Stockholder Nominations and Proposals. Our bylaws establish advance notice procedures with respect to stockholder proposals and the
nomination of candidates for election as directors, other than nominations made by or at the direction of the board of directors or a committee of the board of directors.
|
|
• |
Board Classification. Our board of directors is divided into three classes. The directors in each class will serve for a three-year term, one class being elected each year
by our stockholders. This system of electing and removing directors may tend to discourage a third party from making a tender offer or otherwise attempting to obtain control of us, because it generally makes it more difficult for
stockholders to replace a majority of the directors.
|
|
• |
Stockholder Meetings; Limits on Ability of Stockholders to Act by Written Consent. We have provided in our certificate of incorporation that our stockholders may not act by
written consent. This limit on the ability of our stockholders to act by written consent may lengthen the amount of time required to take stockholder actions. As a result, a holder controlling a majority of our capital stock would not be
able to amend our bylaws or remove directors without holding a meeting of our stockholders called in accordance with our bylaws.
|
|
• |
Amendment of Bylaws. Any amendment of our bylaws requires approval by holders of at least two-thirds of our outstanding capital stock entitled to vote generally in the
election of directors.
|
|
• |
prior to the date of the transaction, the board of directors of the corporation approved either the business combination or the transaction which resulted in the stockholder becoming an interested stockholder.
|
|
• |
the stockholder owned at least 85% of the voting stock of the corporation outstanding at the time the transaction commenced, excluding for purposes of determining the number of shares outstanding (a) shares owned by
persons who are directors and also officers, and (b) shares owned by employee stock plans in which employee participants do not have the right to determine confidentially whether shares held subject to the plan will be tendered in a tender or
exchange offer; or
|
|
• |
on or subsequent to the date of the transaction, the business combination is approved by the board and authorized at an annual or special meeting of stockholders, and not by written consent, by the affirmative vote
of at least two-thirds of the outstanding voting stock that is not owned by the interested stockholder.
|
Name of Entity
|
Jurisdiction of
Incorporation or
Organization
|
|
VirnetX Japan Corporation
|
Japan
|
|
VirnetX Inc.
|
Delaware
|
1. |
I have reviewed this Annual Report on Form 10-K of VirnetX Holding Corporation for the fiscal year ended December 31, 2020;
|
2. |
Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in
light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
|
3. |
Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial
condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
|
4. |
The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules
13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
|
|
(a) |
Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material
information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
|
|
(b) |
Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide
reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
|
|
(c) |
Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the
disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
|
|
(d) |
Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter
that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and
|
5. |
The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s
auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):
|
|
(a) |
All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely
affect the registrant’s ability to record, process, summarize and report financial information; and
|
|
(b) |
Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial
reporting.
|
/s/ Kendall Larsen
|
|
Kendall Larsen
|
|
President and Chief Executive Officer
|
|
(Principal Executive Officer)
|
|
Date: March 16, 2021
|
1. |
I have reviewed this Annual Report on Form 10-K of VirnetX Holding Corporation for the fiscal year ended December 31, 2020;
|
2. |
Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in
light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
|
3. |
Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial
condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
|
4. |
The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules
13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
|
|
(a) |
Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material
information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
|
|
(b) |
Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide
reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
|
|
(c) |
Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the
disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
|
|
(d) |
Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter
that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and
|
5. |
The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s
auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):
|
|
(a) |
All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely
affect the registrant’s ability to record, process, summarize and report financial information; and
|
|
(b) |
Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial
reporting.
|
/s/ Richard H. Nance
|
|
Richard H. Nance
|
|
Chief Financial Officer
|
|
(Principal Accounting and Financial Officer)
|
|
Date: March 16, 2021
|
|
(1) |
The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and
|
|
(2) |
The information contained in the Report fairly presents, in all material respects, the financial condition and result of operations of the Company.
|
/s/ Kendall Larsen
|
|
Kendall Larsen
|
|
President and Chief Executive Officer
|
|
(Principal Executive Officer)
|
|
Date: March 16, 2021
|
|
(1) |
The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and
|
|
(2) |
The information contained in the Report fairly presents, in all material respects, the financial condition and result of operations of the Company.
|
|
/s/ Richard H. Nance
|
|
Richard H. Nance
|
|
Chief Financial Officer
|
|
(Principal Accounting and Financial Officer)
|
Date: March 16, 2021
|